A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

BACKGROUND: Cancer cachexia is a syndrome of progressive weight loss. Non-small cell lung cancer patients experience a high incidence of cachexia of 61%. Research into methods to combat cancer cachexia in various tumour sites has recently progressed to the combination of agents. The combination of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Elaine S, MacLeod, Roderick D, Stewart, Joanna, Bird, Stephen P, Keogh, Justin WL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252396/
https://www.ncbi.nlm.nih.gov/pubmed/22111896
http://dx.doi.org/10.1186/1471-2407-11-493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252396/
https://www.ncbi.nlm.nih.gov/pubmed/22111896
http://dx.doi.org/10.1186/1471-2407-11-493

Ejemplares similares